These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 16025264

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
    Gatza E, Okada CY.
    J Immunol; 2002 Nov 01; 169(9):5227-35. PubMed ID: 12391241
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8+ T cell response.
    Wong CP, Okada CY, Levy R.
    J Immunol; 1999 Feb 15; 162(4):2251-8. PubMed ID: 9973501
    [Abstract] [Full Text] [Related]

  • 5. Combined immunotherapy with whole tumor lysate-pulsed interleukin-15-activated dendritic cells and cucurbitacin I promotes strong CD8(+) T-cell responses and cures highly aggressive lymphoma.
    Hira SK, Mondal I, Manna PP.
    Cytotherapy; 2015 May 15; 17(5):647-64. PubMed ID: 25769790
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
    Tatsumi T, Takehara T, Kanto T, Miyagi T, Kuzushita N, Sugimoto Y, Jinushi M, Kasahara A, Sasaki Y, Hori M, Hayashi N.
    Cancer Res; 2001 Oct 15; 61(20):7563-7. PubMed ID: 11606395
    [Abstract] [Full Text] [Related]

  • 8. IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity.
    Sikora AG, Jaffarzad N, Hailemichael Y, Gelbard A, Stonier SW, Schluns KS, Frasca L, Lou Y, Liu C, Andersson HA, Hwu P, Overwijk WW.
    J Immunol; 2009 Jun 15; 182(12):7398-407. PubMed ID: 19494262
    [Abstract] [Full Text] [Related]

  • 9. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F.
    Cancer Immunol Immunother; 2004 Nov 15; 53(11):963-77. PubMed ID: 15146294
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Potent immunotherapy against well-established thymoma using adoptively transferred transgene IL-6-engineered dendritic cell-stimulated CD8+ T-cells with prolonged survival and enhanced cytotoxicity.
    Kalyanasundaram Bhanumathy K, Zhang B, Xie Y, Xu A, Tan X, Xiang J.
    J Gene Med; 2015 Nov 15; 17(8-9):153-60. PubMed ID: 26212685
    [Abstract] [Full Text] [Related]

  • 12. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.
    Mattarollo SR, West AC, Steegh K, Duret H, Paget C, Martin B, Matthews GM, Shortt J, Chesi M, Bergsagel PL, Bots M, Zuber J, Lowe SW, Johnstone RW, Smyth MJ.
    Blood; 2012 Oct 11; 120(15):3019-29. PubMed ID: 22932803
    [Abstract] [Full Text] [Related]

  • 13. Tocotrienols are good adjuvants for developing cancer vaccines.
    Hafid SR, Radhakrishnan AK, Nesaretnam K.
    BMC Cancer; 2010 Jan 06; 10():5. PubMed ID: 20051142
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Vitamin C treatment of mouse bone marrow-derived dendritic cells enhanced CD8(+) memory T cell production capacity of these cells in vivo.
    Jeong YJ, Kim JH, Hong JM, Kang JS, Kim HR, Lee WJ, Hwang YI.
    Immunobiology; 2014 Jul 06; 219(7):554-64. PubMed ID: 24698552
    [Abstract] [Full Text] [Related]

  • 18. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
    Hu HM, Winter H, Urba WJ, Fox BA.
    J Immunol; 2000 Oct 15; 165(8):4246-53. PubMed ID: 11035058
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.